Skin Analytics has raised £15 million in a Series B round led by Intrepid Growth Partners, following its recent EU MDR Class III CE mark approval for its AI medical device, DERM—the first AI tool globally authorised to make independent clinical decisions on skin cancer without human input.
The new funding will support international expansion into markets such as Europe, Australia, and the US, as well as the development of products to address broader dermatological concerns.
DERM has already been deployed at 26 NHS sites, helping over 150,000 patients and detecting more than 14,000 cancers. The system can autonomously discharge up to 40% of urgent suspected skin cancer cases and reduces unnecessary face-to-face appointments by up to 95%. It surpasses dermatologist accuracy, ruling out high-risk cancers 99.8% of the time.
Healthcare systems globally are facing a critical shortage of dermatologists, with Europe averaging just 30 per million people. Skin Analytics aims to meet this gap by using AI to increase access and efficiency.
